DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Astex Pharmaceuticals, NCIC Clinical Trials Group, and National Cancer Institute (NCI).
There are twenty-two US patents protecting this investigational drug and two hundred and twenty-eight international patents.
Recent Clinical Trials for AT7519
|Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery||National Cancer Institute (NCI)||Phase 1|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia||Astex Pharmaceuticals||Phase 2|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia||NCIC Clinical Trials Group||Phase 2|
Top disease conditions for AT7519
Top clinical trial sponsors for AT7519
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AT7519||See Pricing||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||See Pricing|
|AT7519||See Pricing||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||See Pricing|
|AT7519||See Pricing||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|